"L'Institut Paoli-Calmettes est chargé, par la loi, d'une mission de service public en matière de cancérologie. L’Institut Paoli-Calmettes, notamment à travers son nouveau projet d’établissement s’enracine dans le socle des valeurs communes aux centres de lutte contre le cancer dont l’IPC fait partie :- la quête d’excellence,- la solidarité, - l’humanité, - l’innovation dans la relation aux patients."

During the past decade, Institut PAOLI-CALMETTES conducted 389 clinical trials. In the 10-year time frame, 389 clinical trials started and 79 clinical trials were completed, i.e. on average, 20.3% percent of trials that started reached the finish line to date. In the past 5 years, 163 clinical trials started and 49 clinical trials were completed. i.e. 30.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut PAOLI-CALMETTES" #1 sponsor was "Institut Paoli-Calmettes" with 112 trials, followed by "UNICANCER" with 80 trials sponsored, "Centre Leon Berard" with 27 trials sponsored, "Groupe Francophone des Myelodysplasies" with 25 trials sponsored and "Hoffmann-La Roche" with 25 trials sponsored. Other sponsors include 430 different institutions and companies that sponsored additional 159 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut PAOLI-CALMETTES" #1 collaborator was "National Cancer Institute, France" with 18 trials as a collaborator, "AstraZeneca" with 15 trials as a collaborator, "Roche Pharma AG" with 15 trials as a collaborator, "Ministry of Health, France" with 9 trials as a collaborator and "Novartis" with 8 trials as a collaborator. Other collaborators include 403 different institutions and companies that were collaborators in the rest 268 trials.

According to Clinical.Site data, the most researched conditions in "Institut PAOLI-CALMETTES" are "Breast Cancer" (55 trials), "Myelodysplastic Syndromes" (30 trials), "Acute Myeloid Leukemia" (27 trials), "Multiple Myeloma" (25 trials) and "Prostate Cancer" (22 trials). Many other conditions were trialed in "Institut PAOLI-CALMETTES" in a lesser frequency.

Most popular intervention types in "Institut PAOLI-CALMETTES" are "Drug" (472 trials), "Other" (96 trials), "Procedure" (91 trials), "Biological" (47 trials) and "Radiation" (40 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Gemcitabine" (17 trials), "Azacitidine" (16 trials), "Carboplatin" (15 trials) and "Dexamethasone" (15 trials). Other intervention names were less common.

The vast majority of trials in "Institut PAOLI-CALMETTES" are 560 trials for "All" genders, 104 trials for "Female" genders and 39 trials for "Male" genders.

Currently, there are NaN active trials in "Institut PAOLI-CALMETTES". 7 are not yet recruiting, 162 are recruiting, 95 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 329 completed trials in Institut PAOLI-CALMETTES, 3 suspended trials, and 51 terminated clinical trials to date.

Out of the total trials that were conducted in Institut PAOLI-CALMETTES, 79 "Phase 1" clinical trials were conducted, 263 "Phase 2" clinical trials and 218 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 96 trials that are defined as “Not Applicable".

Institut PAOLI-CALMETTES has several departments that took part in Clinical trials: "Institut Paoli-Calmettes - Hématologie Clinique" - 13 trials